Strategies to prevent and treat cardiovascular risk in cancer patients

Seminars in Oncology

Volumn 40, Issue 2, 2013, Pages 186-198

  Cardinale, Daniela ^a   Bacchiani, Giulia ^a   Beggiato, Marta ^a   Colombo, Alessandro ^a   Cipolla, Carlo M ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMIFOSTINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CARDIAC AGENT; CARVEDILOL; DEFEROXAMINE; DOXORUBICIN; ENZYME INHIBITOR; ERYTHROPOIETIN; ETHYLENEDIAMINE; FLUINDOSTATIN; GLUTATHIONE; NEBIVOLOL; PROBUCOL; RAZOXANE; RETINOL; SELENIUM; TELMISARTAN; TROPONIN I; TROPONIN T; UBIDECARENONE; VALSARTAN;

ACUTE CORONARY SYNDROME; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; HYPERTENSION; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; THROMBOEMBOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; EARLY DIAGNOSIS; HUMANS; NEOPLASMS; RISK FACTORS; STROKE VOLUME; TROPONIN;

EID: 84875730564     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.01.008     Document Type: Article

References (79)

1. T.M. Suter, M.S. Ewer Cancer drugs and the heart: importance and management Eur Heart J 2012 July 12 10.1093/eurheart/ehs181 Epub www.eurheart.oxofordjournal.org
2. E.T. Yeh, C.L. Bickford Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management J Am Coll Cardiol 53 2009 2231 2247
3. American Cancer Society Cancer Facts & Figures Cancer, 2010 www.cancerfactsfigures/cancerfactsfigures/cancerfacts-and-figures-2010
4. D. Cardinale A new frontier: cardioncology Cardiologia 41 1996 887 891
5. A. Albini, G. Pennesi, F. Donatelli, R. Cammarota, S. De Flora, D.M. Noonan Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention J Natl Cancer Inst 102 2010 14 25
6. A. Zambelli, M.D. Porta, V. Rosti From cancer patients to cancer survivors: the issue of cardioncology - a biological perspective Eur J Cancer 46 2010 697 702
7. G. Minotti, E. Salvatorelli, P. Menna Pharmacological foundations of cardio-oncology J Pharmacol Exp Ther 334 2010 2 8
8. D.J. Lenihan, D. Cardinale, C.M. Cipolla The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society Progr Cardiovasc Dis 334 2010 2 8
9. R.A. Hong, T. Limura, K.N. Sumida, R.M. Eager Cardio-oncology/onco- cardiology Clin Cardiol 33 2010 733 737
10. E.T. Yeh Cardiotoxicity induced by chemotherapy and antibody therapy Annu Rev Med 57 2006 485 498 (Pubitemid 43262003)
11. P. Menna, E. Salvatorelli, G. Minotti Cardiotoxicity of antitumor drugs Chem Res Toxicol 21 2008 978 989
12. M.T. Meinardi, J.A. Gietema, D.J. van Veldhuisen, W.T. van der Graaf, E.G. de Vries, D.T. Sleijfer Long-term chemotherapy-related cardiovascular morbidity Cancer Treat Rev 26 2000 429 447 (Pubitemid 32094861)
13. A.W. van den Belt-Dusebout, J. Nuver, R. de Wit Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer J Clin Oncol 24 2006 467 475 (Pubitemid 46630466)
14. J.J. Doyle, A.I. Neugut, J.S. Jacobson, V.R. Grann, D.L. Hershman Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study Clin Oncol 23 2005 8597 8605 (Pubitemid 46211501)
15. L.W. Jones, M.J. Haykowsky, J.J. Swartz, P.S. Douglas, J.R. Mackey Early breast cancer therapy and cardiovascular injury J Am Coll Cardiol 50 2007 1435 1441 (Pubitemid 47494586)
16. A.R. Menezes, C.J. Lavie, R.V. Milani, J. O'Keefe, T.J. Lavie Psychological risk factors and cardiovascular disease: is it all in your head? Postgrad Med 123 2011 165 176
17. D. Cardinale, M. Salvatici, M.T. Sandri Role of biomarkers in cardioncology Clin Chem Lab Med 49 2011 1937 1948
18. D.M. Lloyd-Jones, A.R. Dyer, R. Wang, M.L. Daviglus, P. Greenland Risk factor burden in middle age and lifetime risk for cardiovascular and non-cardiovascular death (Chicago Heart Association Detection Project in Industry) Am J Cardiol 99 2007 535 540 (Pubitemid 46215561)
19. R. Altena, P.J. Perik, D.J. van Veldhuisen, E.G. de Vries, J.A. Gietema Cardiovascular toxicity caused by cancer treatment: strategies for early detection Lancet Oncol 10 2009 391 399
20. D. Cardinale, M.T. Sandri Role of biomarkers in chemotherapy-induced cardiotoxicity Prog Cardiovasc Dis 53 2010 88 93
21. J. Yeboah, A. Folsom, G. Burke, C. Johnson, J.F. Polak, W. Post Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the Multi-Ethnic Study of Atherosclerosis Circulation 120 2009 502 509
22. M.K. Reriani, L.O. Lerman, A. Lerman Endothelial function as a functional expression of cardiovascular risk factors Biomark Med 4 2010 351 360
23. R.O. Bonow, S. Bennett, D.E. Casey Jr ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society of America Circulation 112 2005 1853 1887 (Pubitemid 41368160)
24. G.M. Felker, R.E. Thompson, J.M. Hare Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy N Engl J Med 342 2000 1077 1084 (Pubitemid 30207690)
25. D.D. Von Hoff, M.W. Layard, P. Basa, H.L. Davis Jr, A.L. Von Hoff, M. Rozencweig Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 1979 710 717 (Pubitemid 10218041)
26. M.M. Haq, S.S. Legha, J. Choksi Doxorubicin-induced congestive heart failure in adults Cancer 56 1985 1361 1365 (Pubitemid 15230583)
27. D. Cardinale, A. Colombo, G. Lamantia Anthracycline-induced cardiomyopathy Clinical relevance and response to pharmacologic therapy J Am Coll Cardiol 55 2010 213 220
28. S.A. Hunt, W.T. Abraham, M.H. Chin, A.M. Feldman, G.S. Francis, T.G. Ganiats Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation J Am Coll Cardiol 53 2009 e1 e90
29. T. Eschenhagen, T. Force, M.S. Ewer, G.W. De Keulenaer, T.M. Suter, S.D. Anker Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail 13 2011 1 10
30. J.C. Plana Chemotherapy and the heart Rev Esp Cardiol 64 2011 409 415
31. C.A. Geisberg, D.B. Sawyer Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage Curr Hypertens Rep 12 2010 404 410
32. J.S. Alpert, K. Thygesen, E. Antman, J.P. Bassand Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction J Am Coll Cardiol 36 2000 959 969
33. V.S. Mahajan, P. Jarolim How to interpret elevated cardiac troponin levels Circulation 124 2011 2350 2354
34. P.J. O'Brien Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity Toxicology 245 2008 206 218
35. M. Panteghini The new definition of myocardial infarction and the impact of troponin determination on clinical practice Int J Cardiol 106 2006 298 306 (Pubitemid 41781692)
36. Y. Seino, Y. Tomita, Y. Nagai Cardioprotective effects of ACE-inhibitor (Cilazapril) on adriamycin cardiotoxicity in spontaneously hypertensive rats Circulation 88 1993 I-633
37. E.H. Herman, J. Zhang, S.E. Lipshultz Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin J Clin Oncol 17 1999 2237 2243 (Pubitemid 29318858)
38. S.E. Lipshultz, N. Rifai, S.E. Sallan, S.R. Lipsitz, V. Dalton, D.B. Sacks Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury Circulation 96 1997 2641 2648 (Pubitemid 27451357)
39. S.E. Lipshultz, R.E. Scully, S.R. Lipsitz, S.E. Sallan, L.B. Silverman, T.L. Miller Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial Lancet Oncol 11 2010 950 961
40. D. Cardinale, M.T. Sandri, A. Martinoni Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy J Am Coll Cardiol 36 2000 517 522
41. D. Cardinale, M.T. Sandri, A. Martinoni, E. Borghini, M. Civelli, G. Lamantia Myocardial injury revealed by plasma troponin I in breast cancer treatment with high dose chemotherapy Ann Oncol 13 2002 710 715 (Pubitemid 34567376)
42. M.T. Sandri, D. Cardinale, L. Zorzino, R. Passerini, P. Lentati, A. Martinoni Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy Clin Chem 49 2003 248 252 (Pubitemid 36143446)
43. D. Cardinale, M.T. Sandri, A. Colombo, N. Colombo, M. Boeri, G. Lamantia Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy Circulation 109 2004 2749 2754 (Pubitemid 38737923)
44. H.W. Auner, C. Tinchon, W. Linkesch, A. Tiran, F. Quehenberger, H. Link Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies Ann Hematol 82 2003 218 222 (Pubitemid 36701012)
45. G. Specchia, C. Buquicchio, N. Pansini, F. Di Serio, V. Liso, D. Pastore Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines J Lab Clin Med 145 2005 212 220 (Pubitemid 40692404)
46. S. Kilickap, I. Barista, E. Akgul, K. Aytemir, S. Aksoyek, S. Aksoy cTnT can be a useful marker for early detection of anthracycline cardiotoxicity Ann Oncol 16 2005 798 804 (Pubitemid 40767103)
47. D. Cardinale, A. Colombo, R. Torrisi, M.T. Sandri, M. Civelli, M. Salvatici Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation J Clin Oncol 28 2010 3910 3916
48. P.G. Morris, C. Chen, R.M. Steingart, M. Fleisher, N. Lin, B. Moy Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib Clin Cancer Res 17 2011 3490 3499
49. M. Schmidinger, C.C. Zielinski, U.M. Vogl, A. Bojic, M. Bojic, C. Schukro Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 26 2008 5204 5212
50. T. Reichlin, W. Hochholzer, S. Bassett Early diagnosis of myocardial infarction with sensitive cardiac troponin assays N Engl J Med 361 2009 858 867
51. H. Sawaya, I.A. Sebag, J.C. Plana, J.L. Januzzi, B. Ky, T.C. Tan Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes and trastuzumab Circ Cardiovasc Imaging 5 2012 596 603
52. J.A. De Lemos, D.K. McGuire, M.H. Drazner B-type natriuretic peptide in cardiovascular disease Lancet 362 2003 316 322 (Pubitemid 36936846)
53. K.A. Wouters, L.C. Kremer, T.L. Miller, E.H. Herman, S.E. Lipshultz Protecting against anthracyclines-induced myocardial damage: a review of the most promising strategies Br J Haematol 131 2005 561 578 (Pubitemid 43899624)
54. D. Cardinale, A. Colombo, C.M. Cipolla Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy Curr Treat Options Cardiovasc Med 10 2008 486 495
55. P. Spallarossa, S. Garibaldi, P. Altieri, P. Fabbi, V. Manca, S. Nasti Carvedilol prevents doxorubicin-induced free radicals release and apoptosis in cardiomyocytes in vitro J Mol Cell Cardiol 37 2004 837 846 (Pubitemid 39222076)
56. N. Kalay, E. Basar, I. Ozdogru, O. Er, Y. Cetinkaya, A. Dogan Protective effects of carvedilol against anthracyclines-induced cardiomyopathy J Am Coll Cardiol 48 2006 2258 2262 (Pubitemid 44855419)
57. M.G. Kaya, M. Ozkan, O. Gunebakmaz, H. Akkaya, E.G. Kaya, M. Akpek Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study Int J Cardiol 2012 June 22 Epub
58. E.C. Van Dalen, H.N. Caron, H.O. Dickinson, L.C. Kremer Cardioprotective interventions for cancer patients receiving anthracyclines Cochrane Database Syst Rev 6 2011 CD003917
59. S.E. Lipshultz, N. Rifai, V.M. Dalton, D.E. Levy, L.B. Silverman, S.R. Lipsitz The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia N Engl J Med 351 2004 145 153 (Pubitemid 38886649)
60. W.W. Huh, N. Jaffe, J.B. Durand, M.F. Munsell, C.E. Herzog Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus continuous infusion Pediatr Hematol Oncol 27 2010 546 557
61. C.K. Tebbi, W.B. London, D. Friedman, D. Villaluna, P.A. De Alarcon, L.S. Constine Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease J Clin Oncol 25 2007 493 500 (Pubitemid 350002954)
62. E.V. Barry, L.M. Vrooman, S.E. Dahlberg, D.S. Neuberg, B.L. Asselin, U.H. Athale Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane J Clin Oncol 26 2008 1106 1111
63. E. Barry, J.A. Alvarez, R.E. Scully, T.L. Miller, S.E. Lipshultz Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management Expert Opin Pharmacother 8 2007 1039 1058 (Pubitemid 46929299)
64. H. Nakamae, K. Tsumura, Y. Terada, T. Nakane, M. Nakamae, K. Ohta Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone Cancer 104 2005 2492 2498 (Pubitemid 41691573)
65. C. Cadeddu, A. Piras, G. Mantovani Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment Am Heart J 160 2010 487.e1 487.e7 www.ahjonline.com
66. D. Cardinale, A. Colombo, M.T. Sandri, G. Lamantia, N. Colombo, M. Civelli Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 2006 2474 2481 (Pubitemid 44901520)
67. G.J. Yoong, M.L. Telli, D.P. Kao, K.Y. Matsuda, R.W. Carlson, R.M. Witteles Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies J Am Coll 56 2010 1644 1650
68. J.H. Silber, A. Cnaan, B.J. Clark, S.M. Paridon, A.J. Chin, J. Rychik Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines J Clin Oncol 22 2004 820 828 (Pubitemid 41103593)
69. J.A. Tallaj, V. Franco, B.K. Rayburn, L. Pinderski, R.L. Benza, S. Pamboukian Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure J Heart Lung Transplant 24 2005 2196 2201 (Pubitemid 41814746)
70. G. Curigliano, D. Cardinale, T. Suter Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines Ann Oncol 23 2012 vii155 vii166 www.annonc.oxfordjournals.org
71. S.M. Ewer, M.S. Ewer Cardiotoxicity profile of trastuzumab Drug Safety 31 2008 459 467 (Pubitemid 351695459)
72. M.S. Ewer, M.T. Vooletich, J.B. Durand, M.L. Woods, J.R. Davis, V. Valerio Reversibility of trastuzumab-related cardiotoxicity New insight based on clinical course and response to medical treatment J Clin Oncol 23 2005 7820 7826 (Pubitemid 46657379)
73. M.L. Telli, S.A. Hunt, R.W. Carlson, A.E. Guardino Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility J Clin Oncol 25 2007 3525 3533 (Pubitemid 47310891)
74. C.G. Tocchetti, G. Ragone, C. Coppola, D. Rea, G. Piscopo, S. Scala Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge Eur J Heart Fail 14 2012 130 137
75. E.H. Romond, J.H. Jeong, P. Rastogi, S.M. Swain, J.R. Geyer CE, M.S. Ewer Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 2012 September 17 10.1200/JCO.2011.40.0010 Epub www.jco.org
76. J.R. Mackey, M. Clemons, M.A. Coté, D. Delgado, S. Dent, A. Paterson Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group Curr Oncol 15 2008 24 35
77. P.P. Sengupta, D.W. Northfelt, F. Gentile, J.L. Zamorano, B.K. Khandheria Trastuzumab-induced cardiotoxicity: heart failure at the crossroads Mayo Clin Proc 83 2008 197 203 (Pubitemid 351303103)
78. A.L. Jones, M. Barlow, P.J. Barrett-Lee, P.A. Canney, I.M. Gilmour, S.D. Robb Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring Br J Cancer 100 2009 684 692
79. M. Martin, F.J. Esteva, E. Alba, B. Khandheria, L. Pérez-Isla, J.A. Garcìa-Sàenz Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations Oncologist 14 2009 1 11